PLIANT THERAPEUTICS, INC. 8-K

What Happened

• On March 11, 2026, Pliant Therapeutics, Inc. announced its financial results for the fourth quarter ended December 31, 2025 in a press release. That press release is furnished as Exhibit 99.1 to the Form 8-K filed the same day. The filing states the furnished information is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other securities filings.

Key Details

• Announcement date: March 11, 2026.
• Reporting period: fourth quarter ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K signed by Keith Cummings, M.D., MBA, Chief Financial Officer.

Why It Matters

• This 8-K signals that Pliant released its latest quarterly earnings and financial condition update, which investors should review to assess recent revenue, expenses, cash position, and any management commentary.
• Because the release is furnished (not "filed"), the company disclaims Section 18 liability and the content isn’t automatically incorporated by reference into other SEC filings—investors should read the press release itself for the detailed figures and disclosures.